» Articles » PMID: 38060103

Targeting Dysregulated Lipid Metabolism in the Tumor Microenvironment

Overview
Journal Arch Pharm Res
Specialty Pharmacology
Date 2023 Dec 7
PMID 38060103
Authors
Affiliations
Soon will be listed here.
Abstract

The reprogramming of lipid metabolism and its association with oncogenic signaling pathways within the tumor microenvironment (TME) have emerged as significant hallmarks of cancer. Lipid metabolism is defined as a complex set of molecular processes including lipid uptake, synthesis, transport, and degradation. The dysregulation of lipid metabolism is affected by enzymes and signaling molecules directly or indirectly involved in the lipid metabolic process. Regulation of lipid metabolizing enzymes has been shown to modulate cancer development and to avoid resistance to anticancer drugs in tumors and the TME. Because of this, understanding the metabolic reprogramming associated with oncogenic progression is important to develop strategies for cancer treatment. Recent advances provide insight into fundamental mechanisms and the connections between altered lipid metabolism and tumorigenesis. In this review, we explore alterations to lipid metabolism and the pivotal factors driving lipid metabolic reprogramming, which exacerbate cancer progression. We also shed light on the latest insights and current therapeutic approaches based on small molecular inhibitors and phytochemicals targeting lipid metabolism for cancer treatment. Further investigations are worthwhile to fully understand the underlying mechanisms and the correlation between altered lipid metabolism and carcinogenesis.

Citing Articles

Metabolism of cancer cells and immune cells in the initiation, progression, and metastasis of cancer.

Jiang M, Fang H, Tian H Theranostics. 2025; 15(1):155-188.

PMID: 39744225 PMC: 11667227. DOI: 10.7150/thno.103376.


A Graphene-Based Lipid Modulation Nanoplatform for Synergetic Lipid Starvation/Chemo/Photothermal Therapy of Oral Squamous Cell Carcinoma.

Li R, Li Y, Song Z, Gu Y, Jiao X, Wan C Int J Nanomedicine. 2024; 19:11235-11255.

PMID: 39524917 PMC: 11545731. DOI: 10.2147/IJN.S478308.


The Research Progress of Metformin Regulation of Metabolic Reprogramming in Malignant Tumors.

Sui Q, Yang H, Hu Z, Jin X, Chen Z, Jiang W Pharm Res. 2024; 41(11):2143-2159.

PMID: 39455505 DOI: 10.1007/s11095-024-03783-2.


Metabolomic profiling of upper GI malignancies in blood and tissue: a systematic review and meta-analysis.

Balonov I, Mattis M, Jarmusch S, Koletzko B, Heinrich K, Neumann J J Cancer Res Clin Oncol. 2024; 150(7):331.

PMID: 38951269 PMC: 11217139. DOI: 10.1007/s00432-024-05857-5.

References
1.
Hou C, Tain Y, Yu H, Huang L . The Effects of Resveratrol in the Treatment of Metabolic Syndrome. Int J Mol Sci. 2019; 20(3). PMC: 6387422. DOI: 10.3390/ijms20030535. View

2.
Pearce N, YATES J, Berkhout T, Jackson B, Tew D, Boyd H . The role of ATP citrate-lyase in the metabolic regulation of plasma lipids. Hypolipidaemic effects of SB-204990, a lactone prodrug of the potent ATP citrate-lyase inhibitor SB-201076. Biochem J. 1998; 334 ( Pt 1):113-9. PMC: 1219669. DOI: 10.1042/bj3340113. View

3.
Wang C, Li X, Wang Q, Mehendale S, Yuan C . Selective fraction of Scutellaria baicalensis and its chemopreventive effects on MCF-7 human breast cancer cells. Phytomedicine. 2009; 17(1):63-8. PMC: 2789205. DOI: 10.1016/j.phymed.2009.07.003. View

4.
Schroeder B, Steen T, Espinoza I, Venkatapoorna C, Hu Z, Silva F . Fatty acid synthase (FASN) regulates the mitochondrial priming of cancer cells. Cell Death Dis. 2021; 12(11):977. PMC: 8531299. DOI: 10.1038/s41419-021-04262-x. View

5.
Kerk S, Papagiannakopoulos T, Shah Y, Lyssiotis C . Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment. Nat Rev Cancer. 2021; 21(8):510-525. PMC: 10257891. DOI: 10.1038/s41568-021-00375-9. View